Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00662883 · ClinicalTrials.gov registry record · Phase 1

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

A Phase 1 study, sponsored by Javelin Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT00662883 is a Phase 1 study that has completed, run by Javelin Pharmaceuticals. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00662883, a Phase 1 study, has completed, sponsored by Javelin Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

To assess the effects of nasal corticosteroid treatment on the rate and extent of intranasal absorption of PMI-150 (intranasal ketamine HCl)

Interventions

  • DRUG PMI-150 (intranasal ketamine HCl); mometasone furoate

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2007-11
Est. Completion 2008-02
Phase Phase 1

Sponsor

Javelin Pharmaceuticals

9 total trials

What the Registry Record Tells You About NCT00662883

The ClinicalTrials.gov registry entry for NCT00662883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Javelin Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which PMI-150 (intranasal ketamine HCl); mometasone furoate is the first listed.

NCT00662883 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00662883 about?

NCT00662883 is a clinical study titled "Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)". To assess the effects of nasal corticosteroid treatment on the rate and extent of intranasal absorption of PMI-150 (intranasal ketamine HCl)

What is the current status of trial NCT00662883?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-11. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00662883?

The interventions under investigation include: PMI-150 (intranasal ketamine HCl); mometasone furoate (DRUG).

Who is sponsoring clinical trial NCT00662883?

This trial is sponsored by Javelin Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.